Startup | December 05, 2025
Excelsior Sciences raises $95 million for drug discovery with AI-ready chemistry
Excelsior aims to make reshoring affordable and strategic, shielding nations from geopolitical disruptions
Excelsior aims to make reshoring affordable and strategic, shielding nations from geopolitical disruptions
Peapod Bio’s proprietary technologies can efficiently identify inhibitors and binding molecules for virtually any target
Here's a development that aims to keep your blood pressure in check. Literally!
The partnership aims to combine TQx’s in vivo therapeutic expertise with Kytopen’s continuous flow transfection technology
The technology is intended to support imaging-based training, protocol optimisation and surgical planning
Jacobio stated that these findings underscore the potential of glecirasib and sitneprotafib
AEF0217 is a first-in-class CB1 receptor signaling-specific inhibitor
The partnership targets breakthroughs in Alzheimer’s disease, diabetes, cancer, and cell and gene therapy
PLI scheme for Bulk Drugs has a total budgetary outlay of Rs. 6,940 crore
The acquisitions merge DatCard and Sorna’s expertise in clinical data sharing with Avandra’s de-identified patient data aggregation platform
Subscribe To Our Newsletter & Stay Updated
